The need of extended medication of venous thromboembolism (VTE) is still uncertain. However, it is believed that extended therapy with low-dose of Aspirin may be useful in preventing VTE reoccurrence. In a recent study, it is observed that rivaroxaban is an even better option for extended VTE treatment.
While there is conclusive evidence that aspirin plays a role in reducing the risk of clinically relevant venous thromboembolism (VTE) arising in several surgical and non-surgical situations at risk, little is known of the potential of rivaroxaban for the long/term prevention of recurrent VTE other than aspirin. Method In this randomized, double-blind, study, of 3396 patients with venous thromboembolism a daily dose of rivaroxaban was administered (at doses of 20 mg or 10 mg) and 100 mg of aspirin in 50-50 patient respectively. All the study patients had completed 6 to 12 months of…
